William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Hold rating due to a combination of factors tied to both opportunity and uncertainty around Bristol-Myers Squibb’s CELMoD franchise. He acknowledges that the FDA’s acceptance of the iberdomide NDA in relapsed or refractory multiple myeloma, based on MRD negativity and supported by breakthrough designation, validates the drug’s potential and opens a meaningful second-line or later market.
At the same time, Phipps emphasizes that the long-term value of iberdomide and the broader CELMoD platform depends on forthcoming head-to-head data versus Revlimid and Pomalyst, as well as pending PFS and OS results needed for full approval. Given that the most critical readouts extend into 2026–2029, he views the risk‑reward profile as balanced for now, leading him to maintain a neutral, or Hold, stance on BMY shares.
According to TipRanks, Phipps is a 4-star analyst with an average return of 6.6% and a 48.65% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Bristol-Myers Squibb, and Incyte.
In another report released today, TipRanks – xAI also downgraded the stock to a Hold with a $66.00 price target.